{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:28:23Z","timestamp":1788906503206,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:00:00Z","timestamp":1447804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Intravenous immunoglobulin (<jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content>) is a biological agent composed of polyclonal antibodies prepared from a large cohort of human plasma pools. <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> is increasingly used for the treatment of various antibody\u2010mediated diseases, including pemphigus vulgaris (<jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of the study was to evaluate the benefit and safety profiles of high dose <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> therapy in <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content> patients determined by clinical remission, corticosteroid\u2010sparing and immunomodulatory effects, and adverse events at 12 months' follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content> patients underwent 3\u20138 monthly cycles of <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> therapy at a dose of 2\u2009g\/kg per cycle. The pemphigus disease area index (<jats:styled-content style=\"fixed-case\">PDAI)<\/jats:styled-content> score, direct immunofluorescence (<jats:styled-content style=\"fixed-case\">DIF)<\/jats:styled-content>, indirect immunofluorescence (<jats:styled-content style=\"fixed-case\">IIF)<\/jats:styled-content>, and corticosteroid dosage were evaluated before <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> therapy, after each cycle, and at 6 and 12 months' follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The baseline <jats:styled-content style=\"fixed-case\">PDAI<\/jats:styled-content> score was 75.70\u2009\u00b1\u200921.0 and baseline prednisone dosage was 201.60\u2009\u00b1\u200971.7\u2009mg\/day. The <jats:styled-content style=\"fixed-case\">PDAI<\/jats:styled-content> score reduction of 98% was achieved at 12 months' follow up and a corticosteroid dose reduction of 90% corresponded to clinical improvement. The decrease in both values was statistically significant (<jats:italic>P<\/jats:italic>\u2009=\u20090.002, respectively). At 12 months' follow up, seven patients were shown to be negative on <jats:styled-content style=\"fixed-case\">IIF<\/jats:styled-content>, of whom three proved to be negative on <jats:styled-content style=\"fixed-case\">DIF<\/jats:styled-content>. Adverse events were mild and transient and did not require the cessation of <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> induced long\u2010term clinical remission, while displaying a corticocorticosteroid\u2010sparing effect and evoking a long\u2010standing immunomodulatory effect in <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content> patients. The safety profile of <jats:styled-content style=\"fixed-case\">IVIG<\/jats:styled-content> therapy was assessed as good.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajd.12422","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T02:22:38Z","timestamp":1447899758000},"page":"141-144","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["<scp>IVIG<\/scp> therapy in pemphigus vulgaris has corticosteroid\u2010sparing and immunomodulatory effects"],"prefix":"10.1111","volume":"57","author":[{"given":"Danka","family":"Svecova","sequence":"first","affiliation":[{"name":"Department of Dermatovenerology, Faculty of Medicine Comenius University, University Hospital  Bratislava Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8278-7"},{"key":"e_1_2_8_3_1","volume-title":"Pemphigus Vulgaris: Autoimmune Bullous Disease","author":"\u0160vecov\u00e1 D","year":"2015"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.08.004"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.72"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12772"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.01.012"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.052"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01540.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.9.1158"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1471"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.04.001"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12533"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2006.08.011"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.03.046"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2015.01.022"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1179\/1743132815Y.0000000017"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03925.x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2008.00808.x"},{"key":"e_1_2_8_20_1","first-page":"279","article-title":"Management of pemphigus in pediatric patients","volume":"63","author":"G\u00fcrcan H","year":"2011","journal-title":"Minerva Pediatr."}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajd.12422","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajd.12422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T17:47:11Z","timestamp":1695491231000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajd.12422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/ajd.12422"],"URL":"https:\/\/doi.org\/10.1111\/ajd.12422","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]},"assertion":[{"value":"2015-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-10-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}